Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate
Sign Up to like & getrecommendations! Published in 2018 at "CNS Drugs"
DOI: 10.1007/s40263-017-0487-z
Abstract: BackgroundSPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. In accordance with advice from the European Medicines Agency, assessment of cognitive function was a… read more here.
Keywords: dimesylate; study; lisdexamfetamine dimesylate; attention deficit ... See more keywords
P.1.j.030 Cognitive function in children and adolescents with ADHD receiving lisdexamfetamine dimesylate in a 2-year safety study
Sign Up to like & getrecommendations! Published in 2017 at "European Neuropsychopharmacology"
DOI: 10.1016/s0924-977x(17)31353-6
Abstract: • Lisdexamfetamine dimesylate (LDX) is a long-acting prodrug stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD). – SPD489-404 (ClinicalTrials.gov: NCT01328756) was a 2-year, openlabel study of the safety and efficacy of LDX in children and… read more here.
Keywords: year; study; lisdexamfetamine dimesylate; children adolescents ... See more keywords
Lisdexamfetamine Dimesylate (Vyvanse) for the Treatment of Neurogenic Anejaculation
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Men's Health"
DOI: 10.1177/1557988316658640
Abstract: Dear Editor: We report the first successful pharmacologic treatment of neurogenic anejaculation with lisdexamfetamine dimesylate (Vyvanse) in a 22 year-old Caucasian male with a history of pediatric pelvic neuroblastoma. At 2 years of age, the… read more here.
Keywords: dimesylate vyvanse; anejaculation; treatment; lisdexamfetamine dimesylate ... See more keywords
Identification, Characterization and Quantification of Process-Related and Degradation Impurities in Lisdexamfetamine Dimesylate: Identifiction of Two New Compounds
Sign Up to like & getrecommendations! Published in 2018 at "Molecules"
DOI: 10.3390/molecules23123125
Abstract: Twelve impurities (process-related and degradation) in lisdexamfetamine dimesylate (LDX), a central nervous system (CNS) stimulant drug, were first separated and quantified by high-performance liquid chromatography (HPLC) and then identified by liquid chromatography mass spectrometry (LC-MS).… read more here.
Keywords: related degradation; process; lisdexamfetamine dimesylate; process related ... See more keywords